retatrutide 40mg research pen(R&D) research pen delivers 40mg of independently HPLC verified Retatrutide (LY3437943) in a precision pre-filled pen injector format with adjustable click-based dosing of 2.5mg to 10mg per dose. Retatrutide is the first triple GLP-1R/GIPR/GCGR receptor co-agonist to reach Phase 3 clinical research stages and represents the most advanced incretin research compound currently available for laboratory investigation. PeptideCores supplies this 40mg R&D pen with a batch-specific Certificate of Analysis from an independent third-party laboratory included on every order dispatched across Europe. For laboratory research use only — not for human or veterinary use.
What is the retatrutide 40mg research pen?
Retatrutide (LY3437943) is a synthetic acylated peptide with molecular weight 4759.4 g/mol and molecular formula C210H333N57O65S. It was developed as a triple co-agonist at the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR) — making it the first compound in research history to simultaneously activate all three axes of the incretin and glucagon signalling system in a single molecule. This triple receptor engagement profile produces a more complex and integrated metabolic signalling environment in research models than any mono or dual agonist currently available, including Semaglutide (GLP-1R only) and Tirzepatide (GLP-1R/GIPR dual).
The 36 amino acid peptide chain incorporates a C20 fatty diacid chain attached via a linker that enables albumin binding in research models, producing an extended duration of receptor activation that makes once-weekly research administration protocols practical and consistent.
Triple Receptor Mechanism of Action
The research value of Retatrutide lies in its simultaneous engagement of three pharmacologically distinct receptor systems, each contributing unique downstream signalling effects in research models.
GLP-1 receptor agonism drives glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, delayed gastric emptying and central appetite suppression via hypothalamic and brainstem GLP-1R expression. These mechanisms are the most extensively characterised of the three pathways, having been studied in depth through prior research with Semaglutide and other selective GLP-1R agonists.
GIP receptor co-agonism adds incretin pathway amplification beyond what GLP-1R activation alone can achieve, direct effects on adipose tissue lipid metabolism, emerging bone biology research applications and potentiation of insulin secretion through a complementary intracellular signalling route involving GIPR-mediated cAMP elevation distinct from the GLP-1R pathway.
Glucagon receptor agonism is the defining feature that separates Retatrutide from all previously studied incretin peptides. GCGR activation in research models drives hepatic glucose output regulation, thermogenic energy expenditure via brown adipose tissue activation, lipolysis in adipose tissue and hepatic fatty acid oxidation. The net combination of GLP-1R-mediated glucagon suppression alongside direct GCGR agonism creates a uniquely complex and research-relevant metabolic signalling profile that cannot be replicated by any mono or dual agonist and represents the primary focus of advanced metabolic biology research with Retatrutide.
Research Applications
The Retatrutide 40mg R&D pen is designed for research programmes requiring larger compound quantities for extended protocol durations. Primary research applications include metabolic biology investigations studying the integrated effects of triple incretin receptor co-agonism on glucose homeostasis, insulin sensitivity, hepatic lipid metabolism, adipose tissue biology and energy expenditure regulation. The 40mg quantity provides sufficient compound for comparative receptor engagement studies — using Retatrutide alongside Semaglutide and Tirzepatide to investigate the incremental contribution of each additional receptor target to observed metabolic outcomes.
Secondary research applications include hepatic metabolism programmes investigating GCGR-mediated effects on hepatic glucose output and fatty acid oxidation, formulation and stability studies evaluating Retatrutide’s pharmacokinetic profile in pen delivery format and delivery mechanism research comparing pen-format versus lyophilised powder reconstitution approaches for GLP-1 class compounds.
Dosing for Research Protocols
The 40mg pen provides precise adjustable click-based dosing between 2.5mg and 10mg per administration, delivering up to 16 weekly research doses at 2.5mg or 4 doses at the maximum 10mg setting. For research programmes following an escalating protocol, a suggested schedule begins at 2.5mg for weeks 1–4, progressing to 5mg for weeks 5–8, 7.5mg for weeks 9–12 and 10mg for weeks 13–16 based on experimental observations and receptor activity data. Administer once weekly on the same day each week to maintain consistent research conditions across the full protocol duration.
COA Verification and Purity Documentation
Every Retatrutide 40mg R&D pen supplied by PeptideCores is independently HPLC verified at 99%+ purity by an accredited third-party laboratory with no commercial relationship to PeptideCores. The batch-specific Certificate of Analysis included with every order covers HPLC chromatogram data confirming purity at 99%+ and mass spectrometry molecular identity confirmation at 4759.4 g/mol. Researchers requiring COA documentation before placing an order can request the current batch certificate via our contact page. For a full explanation of what a research peptide COA should contain see our peptide supplier with COA guide.
Store refrigerated at 2–8°C throughout the research programme — do not freeze. Unlike lyophilised powder vials which are sealed and stored at −20°C, pre-filled research pens contain the compound in solution and require consistent refrigeration from receipt through to completion of use. Once first administered, use the pen within 28 days and keep refrigerated between research administrations. All PeptideCores Retatrutide 40mg pen orders are dispatched with cold pack packaging to maintain temperature integrity during transit.
Shipping Across Europe
PeptideCores dispatches the Retatrutide 40mg R&D research pen to all European research destinations — UK, Germany, France, Netherlands, Spain, Italy, Belgium, Austria, Sweden, Denmark, Poland, Greece, Portugal, Ireland and all other EU countries — within 24 hours of order confirmation. Cold pack packaging is included as standard on all pen orders. Full tracking is provided from dispatch through to delivery and all European customer data is handled in strict GDPR compliance. Discreet packaging with no reference to contents on the outer packaging is standard on every shipment.
Disclaimer
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, diagnosis, treatment or prevention of any condition or disease. Only qualified researchers should handle this compound in appropriate laboratory settings following all relevant safety guidelines and applicable regulations. PeptideCores makes no therapeutic claims regarding this compound.
Reviews
There are no reviews yet.